https://researchopenworld.com/brief-review-of-enhanced-external-counter-pulsation-eecp/#

Abstract

EECP (Enhanced External Counterpulsation) has been approved by the FDA (Food and Drug Administration) for management of refractory angina (class IIb). EECP uses 3 sets of pneumatic cuffs that sequentially contract during diastole, increasing aortic diastolic pressure, augmenting coronary blood flow and central venous return. EECP has been shown to improve angina symptoms, reduce nitroglycerin use, and improve exercise tolerance in patients with chronic stable angina. EECP has also been shown to be safe and beneficial in patients with symptomatic stable congestive heart failure. It's been postulated that cardiac benefits of EECP are mediated though VEGF and Nitric oxide mediated vasodilatation and angiogenesis. Recently, the Food and Drug Administration (FDA) approved EECP therapy for heart failure patients.